GlassScriptPhysician profile
Surjit Reddy Moolamalla
NPI 1306849310
$3,593.24
in general payments reported to CMS, 2019-2025
27 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $2,080 · 2021: $481 · 2022: $390 · 2023: $145 · 2024: $150 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $1,681.50 | 2020-2022 | |
| Coloplast Corp | $727.11 | 2020-2022 | |
| Abbvie INC. | $175.06 | 2019-2025 | |
| Intuitive Surgical, INC. | $132.20 | 2021-2022 | |
| Sage Therapeutics, LLC | $104.12 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $100.77 | 2021-2024 | Ova1 |
| Medical Device Business Services, INC. | $70.48 | 2024 | Ethicon |
| Bayer Healthcare Pharmaceuticals INC. | $67.37 | 2021-2023 | |
| Coopersurgical, INC. | $58.78 | 2019-2021 | |
| Boston Scientific Corporation | $49.65 | 2025 | Axonics |
| Pfizer INC. | $47.41 | 2021-2023 | |
| Astellas Pharma US INC | $46.02 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $35.95 | 2023-2025 | Slynd |
| Minerva Surgical, INC | $29.47 | 2022-2023 | |
| Organon LLC | $28.65 | 2022-2023 | Nexplanon |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $26.63 | 2021 | |
| Davol INC. | $25.14 | 2021 | |
| Hologic Sales and Service, LLC | $24.64 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $23.47 | 2025 | |
| Olympus America INC. | $22.74 | 2019 | |
| Sumitomo Pharma America, INC. | $20.35 | 2023 | Myfembree |
| Sanofi Pasteur INC. | $20.02 | 2025 | |
| Myovant Sciences INC. | $18.23 | 2022 | |
| Ethicon US, LLC | $16.41 | 2021 | |
| Therapeuticsmd, INC. | $14.23 | 2021 | |
| Merck Sharp & Dohme LLC | $13.53 | 2019 | |
| Agile Therapeutics, INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surjit Moolamalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.